Phase III clinical trial for Staloral® 300 in China

Stallergenes launches a phase III clinical trial for Staloral® 300 in China

Stallergenes S.A. is announcing the launch of a phase III clinical trial for testing the efficacy and tolerance of Staloral^® 300 treatment – sublingual specific immunotherapy – in over 500 adult patients suffering from asthma induced by allergy to mites. The multi-centre trial, which is a randomised double-blind placebo-controlled trial, will make it possible to evaluate sublingual desensitisation treatment for allergic asthma. The trial is being conducted in China, in 14 hospitals. It is being co-ordinated by Professor Yin Jia, Head of the Allergy Department of the Peking University Medical College Hospital. The patients are being monitored continuously for 15 months.

With this trial, Stallergenes is preparing for registering Staloral^® with the Chinese authorities, and is positioning itself strategically on this very high potential market.

ABOUT STALORAL^® 300

Specific immunotherapy (or desensitisation) is recommended by the international experts for allergic rhinitis, allergic rhino-conjunctivitis, and allergic asthma that is of seasonal or perennial nature both in adults and in children aged over 5 years. Staloral^® 300 is a sublingual solution (drops to be deposited under the tongue) of allergen extracts prepared specially for each individual. Prescribed by allergists, Staloral^® 300 is indicated in particular for desensitisation to tree and grass pollens, to dust mites, to mould, and to animal hair or dander.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company specialised in desensitisation treatments for allergy-related respiratory diseases such as allergic rhino-conjunctivitis, allergic rhinitis, and allergic asthma.

In 2007, Stallergenes recorded a turnover of 147 million euros, nearly half of which on markets outside France. A pioneer and leader in sublingual desensitisation treatments, Stallergenes devotes more than 16% of its turnover to Research and Development.

Stallergenes shares are listed on Eurolist, Compartment B of the Euronext Paris Stock Exchange.

Codes: ISIN FR0000065674, Reuters GEN.PA, and Bloomberg GEN.FP

For further information: >www.stallergenes.com

http://www.stallergenes.com